ArticleScience translational medicine2017
Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.
Abstract read
In one paragraph
Article in Science translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 126 papers.
0numbers the graph read from it
0cells of the map it votes in
126citing papers in PubMed
10.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
126 citing papers in PubMed, 209 citations in OpenAlex.
- Multimodal Imaging under Artificial Intelligence Algorithm for the Diagnosis of Liver Cancer and Its Relationship with Expressions of EZH2 and p57.Computational intelligence and neuroscience · 2022Trial
- KDM6A loss enhances oxidative phosphorylation uncovering tissue-level convergent evolution.The EMBO journal · 2026Article
- Systemic epigenetic dysregulation as a driver of ageing and a therapeutic target.Nature reviews. Molecular cell biology · 2026Review
- Regulation of drug resistance in bladder urothelial carcinoma by tumor aerobic glycolysis.Journal of translational medicine · 2025Review
- KDM6A deficiency promotes tumor progression and resistance to cabozantinib treatment in clear cell renal cell carcinoma.Scientific reports · 2025Article
- HIF-independent oxygen sensing via KDM6A regulates ferroptosis.Molecular cell · 2025Article
- GSK343, an inhibitor of EZH2, prevents acquired cisplatin resistance in bladder cancer.Molecular genetics and genomics : MGG · 2025Article
- KDM6A expression loss is frequent in low grade non-invasive urothelial carcinomas of the urinary bladder.Pathologica · 2025Article
- EZH2 suppresses IR-induced ferroptosis by forming a co-repressor complex with HIF-1α to inhibit ACSL4: Targeting EZH2 enhances radiosensitivity in KDM6A-deficient esophageal squamous carcinoma.Cell death and differentiation · 2025Article
- Harnessing the Deubiquitinase USP1 for Targeted Protein Stabilization.Journal of the American Chemical Society · 2025Article
- Parp3 assists muscle function and skeletal muscle differentiation by selectively adjusting H3K27me3 enrichment.iScience · 2025Article
- Regulation of histone H3K27 methylation in inflammation and cancer.Molecular biomedicine · 2025Review
- The Gender-Biased Differential Effect ofCancers · 2025Article
- Overexpression ofBioMed research international · 2025Article
- Hypoxia-Induced Histone Lactylation Drives Cisplatin Resistance in Bladder Cancer by Promoting RBM15-Dependent mResearch (Washington, D.C.) · 2025Article
- CRISPR-Cas9 potential for identifying novel therapeutic targets in muscle-invasive bladder cancer.Nature reviews. Urology · 2025Review
- The role of the LncRNA XIST/miR-15a-5p/MN1 signaling axis in gender disparities in bladder cancer prognosis.Frontiers in immunology · 2025Article
- Unveiling the molecular profile of a prostate carcinoma: implications for personalized medicine.Biology direct · 2024Article
- The impact of mosaic loss of the Y chromosome (mLOY) in men of advanced age.Biogerontology · 2024Review
- Wnt-deficient and hypoxic environment orchestrates squamous reprogramming of human pancreatic ductal adenocarcinoma.Nature cell biology · 2024Article
66 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
33 authors at 6 institutions in 3 countries.
Lian Dee LerLaboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore.ORCID 0000-0001-5838-2804
Sujoy GhoshProgram in Cardiovascular and Metabolic Disorders, Duke-NUS Medical School, Singapore 169857, Singapore.ORCID 0000-0002-7601-165X
Xiaoran ChaiCentre for Computational Biology, Duke-NUS Medical School, Singapore 169857, Singapore.
Aye Aye ThikeDepartment of Pathology, Singapore General Hospital, Singapore, Singapore.ORCID 0000-0002-9116-2325
Hong Lee HengLaboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore.
Ee Yan SiewLaboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore.ORCID 0000-0001-8614-1979
Sucharita DeyCancer Science Institute of Singapore, National University of Singapore, Centre for Life Sciences, Singapore 117456, Singapore.
Liang Kai KohLaboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore.ORCID 0000-0002-0687-3510
Jing Quan LimLaboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore.ORCID 0000-0003-3732-8707
Weng Khong LimLaboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore.ORCID 0000-0003-4391-1130
Swe Swe MyintLaboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore.
Jia Liang LohLaboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore.
Pauline OngLaboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore.ORCID 0000-0001-9367-0000
Xin Xiu SamDepartment of Pathology, Singapore General Hospital, Singapore, Singapore.ORCID 0000-0003-0583-2319
Dachuan HuangLaboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore.
Tony LimDepartment of Pathology, Singapore General Hospital, Singapore, Singapore.
Puay Hoon TanDepartment of Pathology, Singapore General Hospital, Singapore, Singapore.ORCID 0000-0002-1052-8605
Sanjanaa NagarajanLaboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore.
Christopher Wai Sam ChengDepartment of Urology, Singapore General Hospital, Outram Road, Singapore 169608, Singapore.
Henry HoDepartment of Urology, Singapore General Hospital, Outram Road, Singapore 169608, Singapore.
Lay Guat NgDepartment of Urology, Singapore General Hospital, Outram Road, Singapore 169608, Singapore.ORCID 0000-0002-3073-5396
John YuenDepartment of Urology, Singapore General Hospital, Outram Road, Singapore 169608, Singapore.
Po-Hung LinDivision of Urooncology, Department of Urology, Chang Gung University and Memorial Hospital at LinKou, TaoYuan, Taiwan.ORCID 0000-0001-8245-4302
Cheng-Keng ChuangDivision of Urooncology, Department of Urology, Chang Gung University and Memorial Hospital at LinKou, TaoYuan, Taiwan.ORCID 0000-0001-6154-1220
Ying-Hsu ChangDivision of Urooncology, Department of Urology, Chang Gung University and Memorial Hospital at LinKou, TaoYuan, Taiwan.
Wen-Hui WengDepartment of Chemical Engineering and Biotechnology and Graduate Institute of Biochemical and Biomedical Engineering, National Taipei University of Technology, Taipei, Taiwan.ORCID 0000-0002-6021-0451
Steven G RozenProgram in Cancer and Stem Cell Biology, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore.ORCID 0000-0002-4288-0056
Patrick TanProgram in Cancer and Stem Cell Biology, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore.
Caretha L CreasyCancer Epigenetics Discovery Performance Unit, Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426, USA.ORCID 0000-0002-3735-6401
See-Tong PangDivision of Urooncology, Department of Urology, Chang Gung University and Memorial Hospital at LinKou, TaoYuan, Taiwan. teh.bin.tean@singhealth.com.sg songling.poon@gmail.com michael.t.mccabe@gsk.com jacobpang@adm.cgmh.org.tw.ORCID 0000-0002-2064-0828
Michael T McCabeCancer Epigenetics Discovery Performance Unit, Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426, USA. teh.bin.tean@singhealth.com.sg songling.poon@gmail.com michael.t.mccabe@gsk.com jacobpang@adm.cgmh.org.tw.ORCID 0000-0001-5715-9563
Song Ling PoonLaboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore. teh.bin.tean@singhealth.com.sg songling.poon@gmail.com michael.t.mccabe@gsk.com jacobpang@adm.cgmh.org.tw.
Bin Tean TehLaboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore. teh.bin.tean@singhealth.com.sg songling.poon@gmail.com michael.t.mccabe@gsk.com jacobpang@adm.cgmh.org.tw.ORCID 0000-0003-1514-1124
Duke-NUS Medical School · SGSingapore General Hospital · SGLinkou Chang Gung Memorial Hospital · TWNational University of Singapore · SGGlaxoSmithKline (United States) · USNational Taipei University of Technology · TW
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trithorax-like group complex containing KDM6A acts antagonistically to Polycomb-repressive complex 2 (PRC2) containing EZH2 in maintaining the dynamics of the repression and activation of gene expression through H3K27 methylation. In urothelial bladder carcinoma,
Indexed as
Transcription, GeneticAnimalsCell Line, TumorCell ProliferationEnhancer of Zeste Homolog 2 ProteinGene Expression Regulation, NeoplasticHistone DemethylasesInsulin-Like Growth Factor Binding Protein 3Mice, NudeModels, BiologicalNeoplasm InvasivenessNuclear ProteinsPolycomb Repressive Complex 2Urinary Bladder NeoplasmsUrotheliumEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanHistone DemethylasesIGFBP3 protein, humanInsulin-Like Growth Factor Binding Protein 3KDM6A protein, humanNuclear ProteinsPolycomb Repressive Complex 2
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.